SecBot SecBot
8-K ·Filed May 7, 2026

ATRA

Atara Biotherapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed6mo ago SEC0001193125-26-210413
8-K context-dependent: Items 8.01
Actionable Insight • Neutral

The FDA's alignment on a potential path forward is a positive but non-binding step. Resubmission and eventual approval remain uncertain. Monitor for the Q3 2026 update and any interim data releases for clearer catalysts.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$9.93
T+0 close · May 7, 2026 · via day close
Latest settled
−13.90%
T+60 · $8.55
Vs SPY
−17.73%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $9.93entry
  2. T+1 · 6mo ago −16.01%α −16.84% · $8.34
  3. T+5 · 6mo ago +5.54%α +4.03% · $10.48
  4. T+20 · 6mo ago −3.02%α −6.16% · $9.63
  5. T+60 · 4mo ago −13.90%α −17.73% · $8.55
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Atara reported that after a Type A meeting with the FDA, the agency agreed that a single-arm study with an appropriate historical control could support resubmission of the tabelecleucel (tab-cel) BLA. Partner Pierre Fabre plans to submit an updated dataset from the ALLELE study with additional patients and longer follow-up. The company expects a further regulatory update in Q3 2026.

Key Facts

  • FDA agreed a single-arm study with historical control could support tab-cel BLA resubmission.
  • Pierre Fabre intends to submit updated ALLELE study data with more patients and longer follow-up.
  • Next regulatory update expected in Q3 2026.
  • Tab-cel BLA received a Complete Response Letter on January 9, 2026.

Financial Impact

No financial figures disclosed; potential upside if resubmission leads to approval, but timeline and probability uncertain.

Risk Factors

  • Resubmission may not fully address CRL deficiencies.
  • Partner Pierre Fabre controls the BLA and resubmission process.
  • No guarantee of eventual FDA approval.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
70% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-210413
Document: atra-ex99_1.htm0001193125-26-210413
Document: 0001193125-26-210413-index-headers.html0001193125-26-210413
Document: 0001193125-26-210413-index.html0001193125-26-210413
Document: 0001193125-26-210413.txt0001193125-26-210413

Track record

11 reports on ATRA

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 10, 20266d ago S-3 Bearish 5/10 Entry $8.23 to $7.93 Now $6.40 +22.24% ▲ +3.65% +3.29% vs SPY
  2. Nov 10, 20266d ago 8-K Neutral 5/10 Entry $8.23 to $7.93 Now $6.40 −22.24% ▼ −3.65% −3.29% vs SPY
  3. Jun 26, 202620w ago 8-K Neutral 3/10 Entry $11.17 to $11.48 Now $6.40 −42.70% ▲ +2.78% +2.00% vs SPY
  4. Jun 15, 202622w ago 3 Neutral 2/10 Entry $9.62 to $9.67 Now $6.40 −33.47% ▲ +0.52% +1.77% vs SPY
  5. May 7, 202627w ago 8-K Neutral 4/10 Viewing Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
  6. May 7, 202627w ago Insider Cluster Mixed 5/10 Entry $9.93 to $8.34 Now $6.40 −35.55% ▼ −16.01% −16.84% vs SPY
  7. Apr 24, 202629w ago DEFA14A Neutral 3/10 Entry $4.99 to $4.73 Now $6.40 +28.26% ▼ −5.21% −4.73% vs SPY
  8. Mar 17, 202634w ago S-3 Neutral 4/10 Entry $5.00 to $5.12 Now $6.40 +28.00% ▲ +2.40% +2.67% vs SPY
  9. Mar 12, 202635w ago 8-K Neutral 5/10 Entry $6.90 to $6.50 Now $6.40 −7.25% ▼ −5.80% −5.20% vs SPY
  10. Mar 3, 202636w ago 8-K Mixed 6/10 Entry $5.42 to $5.39 Now $6.40 +18.08% ▼ −0.55% −1.31% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 7, 2026